# China NMPA Drug Inspection - Beijing Shuanglu Pharmaceutical Co., Ltd. - Acetaminophen tablets

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/beijing-shuanglu-pharmaceutical-co-ltd/020f46eb-3b4c-45be-9523-727970757a08/
Source feed: China

> China NMPA drug inspection for Beijing Shuanglu Pharmaceutical Co., Ltd. published October 11, 2018. Drug: Acetaminophen tablets. The Tianjin Municipal Market and Quality Supervision and Management Commission issued a drug quality announcement on Oct

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Tianjin Municipal Drug Quality Bulletin (Issue 3, 2018, Serial No. 34)
- Company Name: Beijing Shuanglu Pharmaceutical Co., Ltd.
- Publication Date: 2018-10-11
- Drug Name: Acetaminophen tablets
- Inspection Finding: Non-compliant item: [Appearance]
- Action Taken: The case was investigated and dealt with in accordance with the law.
- Summary: The Tianjin Municipal Market and Quality Supervision and Management Commission issued a drug quality announcement on October 11, 2018, following supervision and sampling inspections conducted throughout 2018. The inspections revealed four batches of drugs that failed to meet established quality standards, highlighting significant concerns regarding product integrity and safety.

Key manufacturers implicated include Hebei Quantai Pharmaceutical Co., Ltd., Beijing Shuguang Pharmaceutical Co., Ltd., Hebei Shunquanlong Pharmaceutical Co., Ltd., and Anguo Huifa Traditional Chinese Medicine Processing Co., Ltd. The specific violations encompassed: Euryale ferox (Hebei Quantai) failing the "Total Ash" test, with supply chain discrepancies; Acetaminophen Tablets (Beijing Shuguang) being "Unqualified" in appearance; Alum (Hebei Shunquanlong) failing for "Ammonium Salt" content and being identified as not manufactured by the stated company, indicating misrepresentation; and Lotus Seed Heart (Anguo Huifa) failing "Content Determination."

These deficiencies represent clear non-compliance with the quality specifications outlined in various editions of the Chinese Pharmacopoeia. Consequently, the municipal market supervision and law enforcement departments have initiated investigations and are pursuing legal actions against the involved parties to address these critical quality control and supply chain integrity failures.

Company: https://www.globalkeysolutions.net/companies/beijing-shuanglu-pharmaceutical-co-ltd/c3126bb9-2f03-4f7f-bca5-48bf87cd4369/